Clinical Genome Resource
Clinical Genome Resource is an NIH-funded research consortium founded in 2013 that provides standardized, expert-curated classifications of gene-disease validity, variant pathogenicity, clinical actionability, and dosage sensitivity to clinical laboratories, geneticists, researchers, and regulators worldwide.
- Company typePrivate
- Founded2013
- HeadquartersBethesda, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Clinical Genome Resource does
Clinical Genome Resource (ClinGen) is a US-based nonprofit research consortium founded in 2013 by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, to define the clinical relevance of genes and genomic variants for use in precision medicine and research. ClinGen operates a centralized, NIH-funded platform that supports expert-driven curation across four core domains: gene-disease validity, variant pathogenicity (using ACMG/AMP guidelines), clinical actionability, and dosage sensitivity, supplemented by somatic cancer variant curation, baseline literature annotation, and curation of submissions to NCBI's ClinVar database. The platform comprises a set of interconnected web interfaces and databases, including the Gene-Disease Validity Curation Interface, the ClinGen Evidence Repository, the Criteria Specification Registry (CSpec), the Actionability Knowledge Repository, the GenCC harmonization database, and the GenomeConnect patient portal, exposed to users through free public access, APIs, and downloadable data files.
The organization is governed by a Steering Committee and staffed through a community-led model involving more than 2,800 contributors across 77 countries and over 100 expert panels (Gene Curation Expert Panels and Variant Curation Expert Panels), supported by a network of Clinical Domain Working Groups and specialized committees covering pharmacogenomics, somatic cancer, copy number variants, HLA, low penetrance alleles, and data access. ClinGen's primary user groups are clinical genetic testing laboratories, clinical geneticists and genetic counselors, genomics researchers, and regulatory bodies, particularly the FDA, which has formally recognized ClinGen's frameworks. The consortium distributes its outputs through partnerships with NCBI ClinVar, CPIC, and PharmGKB, embedding ClinGen classifications directly into the variant interpretation workflows of clinical laboratories worldwide.
ClinGen's business model is that of a publicly funded research resource rather than a commercial enterprise. The organization is sustained by NHGRI grants, with NHGRI acting as primary sponsor; no commercial pricing is published and all databases, tools, and educational materials are provided free of charge. There are no disclosed venture capital or private equity investors, no subsidiaries, and no acquisition history. The structural setup is closer to a public-sector standards body than a venture-backed company, with moat sources rooted in regulatory recognition, accumulated curated data, ecosystem integration with ClinVar and other genomic reference resources, and the voluntary participation of specialized clinical and scientific experts.
Clinical Genome Resource firmographics
Firmographics- Name
- Clinical Genome Resource
- Legal name
- Clinical Genome Resource
- Website
- https://clinicalgenome.org
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Clinical Genome Resource is an NIH-funded research consortium founded in 2013 that provides standardized, expert-curated classifications of gene-disease validity, variant pathogenicity, clinical actionability, and dosage sensitivity to clinical laboratories, geneticists, researchers, and regulators worldwide.
- Ownership category
- akta.pro rank
Clinical Genome Resource industry classification
Industry- Product category
- Clinical Genomics Curation
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Pharmacogenomics (PGx) Decision Support (HLAAANAB)
Keywords
Where Clinical Genome Resource is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Markets served
Clinical Genome Resource business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- NIH Funding: ClinGen is funded by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health. The organization operates as a research consortium rather than a commercial entity.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Clinical Genome Resource product offering
Product offeringCore offering
ClinGen provides expert-curated clinical genomics knowledge through multiple curation activities (gene-disease validity, variant pathogenicity, clinical actionability, dosage sensitivity, somatic cancer variant curation, and baseline annotation) delivered via web-based databases, APIs, and curation interfaces to standardize genome interpretation for clinical medicine and research. The consortium operates more than 100 expert panels and engages over 2,800 contributors across 77 countries to produce consensus-driven, standardized clinical relevance for genes and variants.
Product overview
ClinGen is a centralized NIH-funded resource founded in 2013 by the National Human Genome Research Institute, involving over 2,800 contributors from 77 countries. The platform offers a suite of interconnected curation products: Gene-Disease Validity Curation and Variant Pathogenicity Curation form the core products for assessing whether genes cause disease and which variants are pathogenic; Clinical Actionability Curation and Dosage Sensitivity Curation address clinical utility and copy number effects; additional products include Somatic Cancer Variant Curation, Baseline Annotation for literature curation, and ClinGen's ClinVar curation work. These products are supported by specialized interfaces (Gene-Disease Validity Curation Interface, Actionability Knowledge Repository, ClinGen Evidence Repository, Criteria Specification Registry) and resources (GenCC Database, GenomeConnect patient portal, ClinGen Lab List, Variant Classification Guidance). The platform enables expert panels to develop disease-specific specifications and disseminate standardized genomic knowledge for precision medicine.
Differentiator
Problem solved
Functional benefit
Products and services
- Gene-Disease Validity Curation Expert-panel curation of the clinical validity of gene-disease associations, providing standardized evidence-based assessments used by clinical laboratories, clinicians, and researchers interpreting genomic findings.
- Variant Pathogenicity Curation Expert-panel curation of genetic variant classifications using standardized ACMG/AMP-based criteria to determine pathogenicity, delivered to clinical laboratories and clinicians interpreting variants.
- Clinical Actionability Curation Expert-panel curation of clinical actionability for gene-variant pairs, assessing whether interventions are available and effective for patients carrying specific genetic findings, intended for clinicians, laboratories, and guideline developers.
- Dosage Sensitivity Curation Expert-panel curation of dosage sensitivity for genes and genomic regions, evaluating haploinsufficiency and triplosensitivity to inform the interpretation of copy-number and structural variants.
- Somatic Cancer Variant Curation Expert-panel curation of somatic variants in cancer, applying standardized oncogenicity classification frameworks to support oncologists, cancer geneticists, and molecular tumor boards.
- GenomeConnect Patient Portal Patient-facing online portal that supports the GenomeConnect registry, enabling patients and families to contribute health and genomic data for clinical genomics research.
- GenCC Database
Quantifiable outcome
- Comprehensive curation of gene-disease validity relationships used globally for clinical decision support
- +1 more outcomes
Companies that use Clinical Genome Resource
Customer profileSegments4 records
Ideal customer profiles3 records
Clinical Genome Resource technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature7 records
Clinical Genome Resource partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- ClinVar (NCBI)coreClinGen has a formal partnership with ClinVar, the NCBI database of genetic variants. Expert panels submit curated variant classifications to ClinVar, creating the primary integration point for clinical variant data. This partnership ensures ClinGen curations reach clinical laboratories worldwide.
- CPIC (Clinical Pharmacogenetics Implementation Consortium)coreClinGen maintains a partnership with CPIC and PharmGKB for pharmacogenomics interpretation, combining expertise in gene-disease curation with pharmacogenomic variant interpretation.
- PharmGKBcorePartnership for pharmacogenomics data integration, linking ClinGen's gene curation work with drug-gene variant interpretation resources.
- FDA (Food and Drug Administration)coreClinGen has received FDA recognition for its curation frameworks and variant classification guidelines, indicating regulatory acceptance of ClinGen standards for clinical genomics.
Scale indicators3 records
Recent moves6 records
Expansion highlights4 records
Clinical Genome Resource competitors and assessment
Company assessmentDirect peers
- CPIC (Stanford / St. Jude Children's Research Hospital): CPIC provides peer-reviewed clinical guidelines for pharmacogenomic variant interpretation. Comparable to ClinGen for clinical actionability curation in the PGx space and a formal partner for joint curation activities.
- CIViC (Washington University in St. Louis): CIViC is an open-access, expert-curated platform for clinical interpretations of variants in cancer. Directly comparable as a peer curation platform integrated with ClinGen for somatic variant interpretation work.
- DECIPHER (Wellcome Sanger Institute): DECIPHER is a database of genomic variation and associated phenotypes in patients with rare conditions. Comparable to ClinGen for clinical genomic data curation supporting interpretation and rare disease diagnosis.
- COSMIC (Wellcome Sanger Institute): COSMIC is a comprehensive database of somatic mutations in human cancer, comparable to ClinGen for its somatic cancer variant curation - an area of overlapping coverage via ClinGen's Somatic Cancer Clinical Domain Working Group.
- LOVD (Leiden University Medical Center): LOVD provides locus-specific open variation databases used by clinical genetics labs globally. Comparable to ClinGen for variant-classification purposes and often used as a complementary resource alongside ClinGen's gene-level curations.
- ClinVar (NCBI/NIH): NCBI's ClinVar is the primary public database of genomic variant interpretations and the principal integration point for ClinGen-curated classifications. Most directly comparable to ClinGen as the dominant variant-interpretation database used by clinical laboratories worldwide.
- PharmGKB (Stanford University): PharmGKB curates knowledge about drug-gene-variant relationships for pharmacogenomics. Comparable to ClinGen for its curated approach to genomic variant interpretation in PGx, and a formal ClinGen partner with overlapping scope in that domain.
Broad incumbents
- gnomAD (Broad Institute): gnomAD provides population-level allele frequencies used by variant interpretation frameworks. Comparable to ClinGen as a reference resource feeding into clinical variant interpretation, though focused on population frequency data rather than curated pathogenicity.
- OMIM (McKusick-Nathans Institute, Johns Hopkins): OMIM is a comprehensive catalog of human genes and genetic phenotypes maintained at Johns Hopkins. Comparable to ClinGen in providing curated gene-disease knowledge, though broader and more phenotype-focused rather than variant-classification-focused.
- HGMD (QIAGEN): The Human Gene Mutation Database is a commercial database of human gene mutations maintained by QIAGEN. Comparable to ClinGen for variant and gene-disease curation, though commercialized and widely licensed by clinical labs alongside ClinGen classifications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Clinical Genome Resource social profiles
Digital presenceClinical Genome Resource financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clinical Genome Resource leadership team
Management profileNumber of profiles
Clinical Genome Resource funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clinical Genome Resource M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clinical Genome Resource
What does Clinical Genome Resource do?
ClinGen provides expert-curated clinical genomics knowledge through multiple curation activities (gene-disease validity, variant pathogenicity, clinical actionability, dosage sensitivity, somatic cancer variant curation, and baseline annotation) delivered via web-based databases, APIs, and curation interfaces to standardize genome interpretation for clinical medicine and research. The consortium operates more than 100 expert panels and engages over 2,800 contributors across 77 countries to produce consensus-driven, standardized clinical relevance for genes and variants.
Is Clinical Genome Resource a public or private company?
Clinical Genome Resource is a private company. It is classified as state government owned and is currently operating.
When was Clinical Genome Resource founded?
Clinical Genome Resource was founded in 2013. It employs 1,001 to 5,000 people.
Where is Clinical Genome Resource based?
Clinical Genome Resource is headquartered in Bethesda, United States, in the North America region.
How does Clinical Genome Resource make money?
One revenue line is on record: NIH Funding.
Who are Clinical Genome Resource's main competitors?
Direct peers on record are CPIC (Stanford / St. Jude Children's Research Hospital), CIViC (Washington University in St. Louis), DECIPHER (Wellcome Sanger Institute), COSMIC (Wellcome Sanger Institute), LOVD (Leiden University Medical Center), ClinVar (NCBI/NIH) and PharmGKB (Stanford University). Broad incumbents are gnomAD (Broad Institute), OMIM (McKusick-Nathans Institute, Johns Hopkins) and HGMD (QIAGEN).
Does Clinical Genome Resource have an API?
Yes. ClinGen provides API access for file downloads and data retrieval. The platform offers APIs for Gene-Disease Validity curations, Dosage Sensitivity data, Clinical Actionability data, and Variant Pathogenicity data. Access is available via the File Downloads & APIs section at search.clinicalgenome.org/kb/downloads. Developer documentation is at search.clinicalgenome.org/kb/downloads.
What industry is Clinical Genome Resource in?
Clinical Genome Resource's product category is Clinical Genomics Curation. Its primary akta.pro industry code is HLAAANAD, Molecular Tumor Boards & Clinical Interpretation Services, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 541714 and its SIC code is 8731.